Interventional Oncology Latest Evidence
Forging clinical partnerships investing in investigator-initiated research
We work with you and invest in research to provide the evidence you need to be confident in recommending proven interventional oncology strategies to your peers and your patients.
For 20 years, we have been making significant investments in advancing clinical data for TheraSphereTM (Y90 SIRT treatment) building evidence of the benefits it offers and increasing our understanding of how to optimise personalised treatment strategies in the treatment of primary liver cancer (hepatocellular carcinoma and cholangiocarcinoma) and of mCRC (colorectal cancer that has metastasised to the liver). Beginning with more advanced stage patients to early-stage HCC with low tumour burden. From bridging and downstaging to lobectomy and segmentectomy, the versatility of TheraSphereTM Y90 Microspheres has been proven in more than 50 publications, and more data is on its way….
Clinical Evidence for Cryoablation
We invest in exploring new cryoablation treatment options for our clinicians and patients in the fight against different types of cancer.
Cryoablation is a minimally invasive and safe alternative to surgery. This therapy is also an alternative for patients who suffer from renal cell carcinoma, lung or prostate cancer and muskuloeskeletal tumours, among others.